Attorneys involved in the Risperdal settlement report that a significant proportion of affected parties—over 5,600 individuals, or about 94% of the up to 6,000 potential claims—have now agreed to the terms of the bulk settlement. As a matter of fact, they claim that virtually all of these claimants, equivalent to 99.9% of the group, have elected to accept their siuted settlement offers.
To round up the lingering directive, holdouts are still in existence. These remaining dissidents cast a stark light on the vast complexity inherent in achieving sweeping, mass resolutions for large-scale pharmaceutical disputes, which involve thousands of plaintiffs spread across different jurisdictions. The difficulty lies not just within the logistical challenges but also the nuanced personal considerations and variables that each claimant must assess.
This accounts for a portion of those ideally hoping to realize more substantial compensation from court victories, despite the inherent uncertainties and significant legal expenses involved with moving forward. Consequently, this mosaical litigation landscape surrounding the Risperdal settlement illustrates the unavoidable tension between the necessity for broad-appeal resolutions in mass tort claims and individual claimants’ preferences and appraisal of personal risk and reward.
For reference and further details pertaining to this case, you may find the related coverage on this topic from the Legal Intelligencer here.